News
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
With more and more people applying for remote positions, how can you stand out among the massive stacks of applications?
Such a deep, data-driven approach is enabling precision medicine, in particular, which is expanding from oncology to autoimmune diseases and other conditions.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The company plans to use the money to boost its drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.
The companies announced that Dupixent was the first biologic to significantly reduce itch and skin lesions in patients with Prurigo Nodularis in the Phase III trial.
AstraZeneca has been struggling to find an effective use for its anti-CTLA-4 antibody tremelimumab. It may have finally found it.
A checkpoint inhibitor under development from China’s CStone Pharmaceuticals hit the mark in a Phase III non-small cell lung cancer study.
A study conducted by 23andMe and published in Nature Genetics identified a genetic risk factor tied to the loss of smell from COVID-19.
Hal Barron, the man who guided the reinvigoration of the pharmaceutical direction at GSK, is departing the company to be the CEO of Altos Labs.
The FDA issued the partial clinical hold order in response to the IND application Yumanity submitted in December last year. The company expects additional data on the directive within the next 30 days.